+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome

Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome

Transfusion 51(3): 504-510

To determine the prevalence and impact of transfusing plasma containing white blood cell antibodies, we compared two high-throughput HLA antibody screening assays and prospectively examined the medical records of all platelet (PLT) recipients to detect subtle manifestations of transfusion-related acute lung injury and other transfusion reactions. Serum samples from 136 plateletpheresis donors were tested for HLA Class I and II antibodies using microbead (LABScreen PRA, One Lambda) and microchip (Dynachip, Invitrogen) assays. Electronic medical records of all recipients were reviewed for vital signs and nursing documentation before and after transfusion. In the microchip assay with a cutoff value of 0.25, 2.9% of samples were positive for Class I and 8.9% for Class II antibodies; with a cutoff value of 0.1, the results were 14.9 and 21.6%, respectively. In the microbead assay (normalized background ratio, 1.5), 15% were positive for Class I and 21% for Class II antibodies. The prevalence of HLA antibodies was 17% in donors without pregnancy or transfusion history and 47% in donors with such history. The PLTs were transfused in 265 episodes to 67 patients. There were no reported reactions; however, symptoms or vital sign changes were noted in seven transfusion episodes. The incidence of reactions was 2.7% (2/75) for antibody-positive units and 2.6% (5/190) for antibody-negative units. Microbead and microchip assays yielded similar results. The prevalence of HLA antibodies was greater in donors with a history of pregnancy or transfusion, but no increase in the incidence of transfusion reactions was noted in recipients of components from donors with HLA antibodies.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055674247

Download citation: RISBibTeXText

PMID: 20849407

DOI: 10.1111/j.1537-2995.2010.02874.x

Related references

A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 51(1): 92-96, 2011

A comparison of two robotic platforms to screen plateletpheresis donors for HLA antibodies as part of a transfusion-related acute lung injury mitigation strategy. Transfusion 50(8): 1766-1777, 2010

Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion 54(12): 3036-3042, 2015

Platforms for high-throughput screening of Wnt/Frizzled antagonists. Drug Discovery Today 17(23-24): 1316-1322, 2013

Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Analytical Biochemistry 328(2): 131-138, 2004

Identification of novel NaV1.7 antagonists using high throughput screening platforms. Combinatorial Chemistry & High Throughput Screening 15(9): 713-720, 2014

High-throughput platforms for the screening of new therapeutic targets for neurodegenerative diseases. Drug Discovery Today 21(9): 1355-1366, 2016

Microfluidics for cell-based high throughput screening platforms - A review. Analytica Chimica Acta 903: 36-50, 2016

Novel Phenotypic Fluorescent Three-Dimensional Platforms for High-throughput Drug Screening and Personalized Chemotherapy. Journal of Cancer 4(5): 402-415, 2013

In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities. Archives of Toxicology (): -, 2016

Functional expression of mammalian opioid receptors in insect cells and high-throughput screening platforms for receptor ligand mimetics. Cellular and Molecular Life Sciences 62(7-8): 919-930, 2005

Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion 48(6): 1174-1179, 2008

Development of FRET assay into quantitative and high-throughput screening technology platforms for protein-protein interactions. Annals of Biomedical Engineering 39(4): 1224-1234, 2011

Stably transformed insect cell lines: tools for expression of secreted and membrane-anchored proteins and high-throughput screening platforms for drug and insecticide discovery. Advances in Virus Research 68: 113-156, 2006

Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China. Plos One 7(5): E37532-E37532, 2012